Opportunity Information: Apply for PAR 23 090
The NIH SIREN Neurologic Clinical Trials funding opportunity (PAR 23-090) is a National Institutes of Health cooperative agreement that supports multi-center, clinical trial required research focused on neurologic emergencies. The main goal is to move promising emergency neurology interventions into well-coordinated, real-world testing across multiple clinical sites, with the work carried out inside the NIH SIREN Network (Strategies to Innovate Emergency Care Clinical Trials Network). Rather than funding isolated single-site studies, this program is set up to run trials that need rapid identification, enrollment, and treatment of patients in time-sensitive emergency settings, where consistent protocols and operational support are critical.
A central feature of this opportunity is that awardees do not operate alone; they work in partnership with NIH and the existing SIREN infrastructure. The SIREN Clinical Coordinating Center (CCC) helps awardees operationalize and execute the study efficiently, including practical trial start-up and implementation coordination across sites. In parallel, the SIREN Data Coordinating Center (DCC) provides statistical leadership and data management support, which typically includes support for study design inputs, data standards, database and reporting systems, quality control, and analytic planning. The SIREN hubs and their affiliated clinical sites are responsible for on-the-ground execution of the clinical protocol, meaning they implement study procedures where patients actually present for emergency care, such as emergency departments and prehospital or acute care pathways depending on the trial.
The FOA is specifically aimed at neurologic emergencies and emphasizes multi-center clinical trials, with SIREN positioned not only to run studies within its U.S. network but also to collaborate with other U.S. and international consortia when larger, definitive trials are needed. This is important because many emergency neurology questions require very large sample sizes and diverse settings to produce reliable, generalizable evidence. The announcement also draws a clear boundary around stroke: multi-center clinical trials in stroke treatment, stroke recovery, or stroke prevention that are supported by NINDS are expected to be conducted in NIH StrokeNet rather than within SIREN. In other words, applicants considering stroke-centric trials should anticipate that the appropriate network home is StrokeNet, while SIREN is intended for other neurologic emergencies.
The award mechanism is UG3/UH3 under a cooperative agreement structure. In practice, UG3/UH3 programs are commonly structured as a phased approach, where an initial stage supports planning and start-up activities and a subsequent stage supports full trial implementation once specific milestones are met. Because this is a cooperative agreement, NIH expects substantial programmatic involvement, meaning the funder is more actively engaged than under a standard grant. The activity category is Health, and the associated CFDA number listed is 93.853. The opportunity is listed as discretionary funding, and the agency is the National Institutes of Health.
Eligibility is broad and includes many types of U.S. organizations and governments. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with or without 501(c)(3) status (outside higher education); for-profit organizations (other than small businesses) as well as small businesses; Native American tribal governments (federally recognized) and tribal organizations (other than federally recognized governments); and public housing authorities/Indian housing authorities. The FOA also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-domestic (non-U.S.) entities (foreign organizations). Importantly, applicants do not need to already be part of SIREN to apply, which lowers the barrier for new investigative teams with strong trial concepts to propose studies that can be integrated into the network.
From a timing standpoint, the original closing date provided is March 6, 2026. Some fields in the listing (such as an award ceiling and expected awards) are not specified in the provided source data, so applicants would typically need to consult the full FOA text and any NIH budget guidance for allowable costs, budget limits, project period expectations, and the details of the UG3-to-UH3 transition milestones.
Overall, this opportunity is designed for teams proposing rigorous, multi-site neurologic emergency trials that benefit from an established national trial infrastructure. It offers the advantage of coordinated operational support (CCC), centralized data and statistical resources (DCC), and access to a network of hubs and clinical sites capable of enrolling and treating patients in fast-moving emergency care environments, while reserving stroke-focused multi-center trials for the separate NIH StrokeNet system.Apply for PAR 23 090
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853.
- This funding opportunity was created on 2023-02-08.
- Applicants must submit their applications by 2026-03-06. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH SIREN Neurologic Clinical Trials (PAR-23-090)
What is this funding opportunity?
This opportunity (PAR-23-090) is an NIH cooperative agreement that supports multi-center, clinical trial required research focused on neurologic emergencies, carried out within the NIH SIREN Network (Strategies to Innovate Emergency Care Clinical Trials Network).
What is the main purpose of the program?
The goal is to move promising emergency neurology interventions into well-coordinated, real-world testing across multiple clinical sites. It is designed for time-sensitive emergency settings where rapid identification, enrollment, and treatment are required and where consistent protocols and strong operational support matter.
What kinds of studies does it prioritize?
It emphasizes multi-center clinical trials (clinical trial required) in neurologic emergencies, particularly trials that need rapid patient enrollment and treatment in emergency care environments.
Is this meant for single-site trials?
No. The program is structured to avoid isolated, single-site studies and instead support trials conducted across multiple sites with coordinated procedures and centralized infrastructure support.
What does it mean that this is a cooperative agreement?
Under a cooperative agreement, NIH expects substantial programmatic involvement. In practical terms, awardees work in partnership with NIH and the existing SIREN infrastructure rather than operating fully independently like a typical grant.
What is the award mechanism for this opportunity?
The mechanism is UG3/UH3. This is commonly a phased approach, with an initial stage supporting planning and start-up activities (UG3) and a later stage supporting full trial implementation (UH3) once specific milestones are met.
How does the UG3 to UH3 transition generally work?
Based on the description provided, the program is typically structured so that planning and start-up occur first, and full implementation follows after meeting defined milestones. The specific milestones and transition details are expected to be described in the full FOA.
Do awardees have to run the trial entirely on their own?
No. A central feature is that awardees partner with NIH and the SIREN infrastructure, which is designed to help operationalize and execute multi-site emergency trials efficiently.
What support does the SIREN Clinical Coordinating Center (CCC) provide?
The CCC helps operationalize and execute the study, including practical trial start-up and implementation coordination across sites.
What support does the SIREN Data Coordinating Center (DCC) provide?
The DCC provides statistical leadership and data management support. This typically includes input on study design, data standards, database and reporting systems, quality control, and analytic planning.
What role do SIREN hubs and affiliated clinical sites play?
SIREN hubs and their affiliated clinical sites handle on-the-ground execution of the clinical protocol, implementing study procedures where patients present for emergency care (for example, emergency departments and prehospital or acute care pathways, depending on the trial).
Can SIREN collaborate beyond its U.S. network?
Yes. The description notes that SIREN is positioned to run studies within its U.S. network and also collaborate with other U.S. and international consortia when larger, definitive trials are needed.
Why does the opportunity emphasize large, multi-center trials?
Many emergency neurology questions require very large sample sizes and diverse settings to produce reliable, generalizable evidence. Multi-center execution helps meet those needs.
Are stroke trials appropriate for this SIREN opportunity?
Stroke is explicitly carved out. Multi-center clinical trials in stroke treatment, stroke recovery, or stroke prevention that are supported by NINDS are expected to be conducted in NIH StrokeNet rather than within SIREN.
If my trial is stroke-centric, what should I do?
Based on the boundary stated here, applicants considering stroke-centric multi-center trials should anticipate that the appropriate network home is NIH StrokeNet, not SIREN.
Do applicants need to already be part of the SIREN Network to apply?
No. The information provided states that applicants do not need to already be part of SIREN to apply, which allows new investigative teams to propose studies that can be integrated into the network.
Who is the funding agency?
The agency is the National Institutes of Health (NIH).
What is the activity category and CFDA number listed?
The activity category is Health, and the associated CFDA number listed is 93.853.
Is this discretionary funding?
Yes. The opportunity is listed as discretionary funding.
What organizations are eligible to apply?
Eligibility is broad and includes many U.S. organizations and governments. The listed eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with or without 501(c)(3) status (outside higher education); for-profit organizations (other than small businesses) as well as small businesses; Native American tribal governments (federally recognized) and tribal organizations (other than federally recognized governments); and public housing authorities/Indian housing authorities.
Are there additional categories of eligible applicants called out?
Yes. The FOA explicitly highlights additional eligible categories including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-domestic (non-U.S.) entities (foreign organizations).
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The information provided indicates that non-domestic (non-U.S.) entities (foreign organizations) are included among the eligible applicant categories.
What is the closing date mentioned for this opportunity?
The original closing date provided is March 6, 2026.
Is the award ceiling or expected number of awards provided?
No. Some fields, such as the award ceiling and expected awards, are not specified in the provided source data.
Where should applicants look for budget limits, allowable costs, and project period details?
Because certain fields are not specified in the provided listing, applicants would typically need to consult the full FOA text and any NIH budget guidance for allowable costs, budget limits, project period expectations, and details of UG3-to-UH3 transition milestones.
What is the practical advantage of running a trial through SIREN?
This opportunity is designed to leverage established national trial infrastructure for fast-moving emergency care environments, including operational support from the CCC, centralized data and statistical resources from the DCC, and access to SIREN hubs and clinical sites capable of enrolling and treating patients quickly and consistently across locations.
Browse more opportunities from the same category: Health
Next opportunity: U.S. Mission to the EU PAS Annual Program Statement
Previous opportunity: FY2022 Battlefield Restoration Grants
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 090
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 090) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research Coordinating Center on the Exposome and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD): Elucidating the Role of Social and Behavioral Determinants of Health in AD/ADRD Etiology and Disparities (U24 Clinical Trial Not Allowed) Apply for RFA AG 24 011 Funding Number: RFA AG 24 011 Agency: National Institutes of Health Category: Health Funding Amount: $5,000,000 |
| Using Multimodal Biomarkers to Differentially Diagnose ADRDs for Clinical Trials (U19 Clinical Trial Optional) Apply for RFA NS 24 001 Funding Number: RFA NS 24 001 Agency: National Institutes of Health Category: Health Funding Amount: $4,700,000 |
| Sexually Transmitted Infections (STI) Cooperative Research Centers (CRC): Vaccine Development (U01 Clinical Trial Not Allowed) Apply for RFA AI 23 008 Funding Number: RFA AI 23 008 Agency: National Institutes of Health Category: Health Funding Amount: $1,400,000 |
| Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection (R01 Clinical Trial Optional) Apply for RFA MD 23 008 Funding Number: RFA MD 23 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care (R01 Clinical Trial Required) Apply for RFA MD 23 007 Funding Number: RFA MD 23 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Networking/Infrastructure Project for Research on Determinants of Differences Among Human and Nonhuman Primate Species in Life Spans, Life Histories, and Other Aging Related Outcomes, and Prospects for Translation (R61/R33 Clinical Trial Not Allowed) Apply for RFA AG 24 020 Funding Number: RFA AG 24 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Comparative Research on Determinants of Differences Among Human and Nonhuman Primate Species in Life Spans, Life Histories, and Other Aging-Related Outcomes, and Prospects for Translation (R01 Clinical Trial Not Allowed) Apply for RFA AG 24 019 Funding Number: RFA AG 24 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| IDeA Networks of Biomedical Research Excellence (INBRE) (P20 Clinical Trial Optional) Apply for PAR 23 100 Funding Number: PAR 23 100 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Expand Family Planning and Sexual and Reproductive Health Activity (ExpandPF) Apply for RFI 624 23 00001 Funding Number: RFI 624 23 00001 Agency: West Africa USAID-Ghana Category: Health Funding Amount: $45,000,000 |
| Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional) Apply for PAR 23 099 Funding Number: PAR 23 099 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional) Apply for PAR 23 106 Funding Number: PAR 23 106 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Community Level Interventions to Improve Minority Health and Reduce Health Disparities (R01 - Clinical Trial Optional) Apply for RFA MD 23 004 Funding Number: RFA MD 23 004 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| AHRQ Improving Diagnostic Safety in Ambulatory Care: Strategies and Preventions (R18) Apply for RFA HS 23 011 Funding Number: RFA HS 23 011 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Dissemination and Implementation of Equity-Focused Evidence-Based Interventions in Healthcare Delivery Systems (R18) Apply for RFA HS 23 002 Funding Number: RFA HS 23 002 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $2,500,000 |
| AHRQ Understanding and Improving Diagnostic Safety in Ambulatory Care: Incidence and Contributing Factors (R01) Apply for RFA HS 23 010 Funding Number: RFA HS 23 010 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Supporting the Management of Substance Use Disorders in Primary Care and other Ambulatory Settings (R18) Apply for RFA HS 23 005 Funding Number: RFA HS 23 005 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $625,000 |
| Genomics Centers for Infectious Diseases (U19 Clinical Trial Not Allowed) Apply for RFA AI 23 015 Funding Number: RFA AI 23 015 Agency: National Institutes of Health Category: Health Funding Amount: $2,850,000 |
| Using Secondary Data Analysis to Determine Whether Preventive Interventions Implemented Earlier in Life Reduce Suicide Risk (U01 Clinical Trial Not Allowed) Apply for RFA MH 23 275 Funding Number: RFA MH 23 275 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Network to Promote Multidisciplinary Mechanistic and Translational Studies of Sickle Cell Disease Pain (U24, Clinical Trial Optional) Apply for RFA AT 24 001 Funding Number: RFA AT 24 001 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Independent Clinical Trial Not Allowed) Apply for RFA AG 24 014 Funding Number: RFA AG 24 014 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 090", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.